IDEAS home Printed from https://ideas.repec.org/a/vrs/manmen/v16y2012i1p203-215n15.html
   My bibliography  Save this article

Pharmaceutical sector in the new reimbursement era

Author

Listed:
  • Kołodziejska Katarzyna

    (GENEXO Sp. z o.o., 26 Gen. Zajączka St., 01-510 Warsaw)

Abstract

Pharmaceutical sector in the new reimbursement era The topics taken into consideration in this article concern the role of pharmaceutical sector in country's economy and the influence of factors limiting economic growth of the branch, mainly provisions of The Act on Reimbursement of Medicines, Foodstuffs Intended for Particular Nutritional Purposes and Medical Devices from 12th of May, 2011. New rules introduced by this Act, affecting the price evolution of the reimbursed products (i.e., official selling price, fixed wholesale and retail margins, retail margin calculated on the basis of wholesale price of the limit-determining product), had an impact on the increase of patient repayment level for the drugs, the decrease of NHF reimbursement and spending level, and the drop of the value of reimbursed drug market. Such a situation caused the increase of patient repayment level for the reimbursed drugs in many disease entities.In spite of many restrictions imposed by the mentioned Act, the perspectives of pharmaceutical market's growth in Poland are positive. In last few months, pharmaceutical sector has been prepared for the entry of new Reimbursement Act. More than 60% of requested pharmaceutical companies estimated positively current market situation in Poland. Among the surveyed ones, increasing sales numbers and improving financial results are indicated as the causes of such estimation (KPMG/PMR Report 2011).Every single pharmaceutical enterprise is the company undergoing the same rules as companies operating in other fields, which means the necessity of profit taking. During the analysis of the pharmaceutical market one can see some complexity and specificity, particularly due to the offered products and the sources of their funding, the level of regulation and the conservatism of the market itself which is one of the highest in the entire business. In spite of numerous limitations, most of enterprises realize the strategy of a continuous growth due to successful selling and marketing activities.

Suggested Citation

  • Kołodziejska Katarzyna, 2012. "Pharmaceutical sector in the new reimbursement era," Management, Sciendo, vol. 16(1), pages 203-215, May.
    • Handle: RePEc:vrs:manmen:v:16:y:2012:i:1:p:203-215:n:15
    DOI: 10.2478/v10286-012-0015-7
    as

    Download full text from publisher

    File URL: https://doi.org/10.2478/v10286-012-0015-7
    Download Restriction: no
    File URL: https://libkey.io/10.2478/v10286-012-0015-7?utm_source=ideas
    LibKey link: if access is restricted and if your library uses this service, LibKey will redirect you to where you can use your library subscription to access this item
    ---><---

    References listed on IDEAS

    as
    1. Zafer Caliskan, 2009. "The relationship between pharmaceutical expenditure and life expectancy: evidence from 21 OECD countries," Applied Economics Letters, Taylor & Francis Journals, vol. 16(16), pages 1651-1655.
    Full references (including those not matched with items on IDEAS)

    Most related items

    These are the items that most often cite the same works as this one and are cited by the same works as this one.
    1. Maik T. Schneider & Ralph Winkler, 2021. "Growth and Welfare under Endogenous Lifetimes," Scandinavian Journal of Economics, Wiley Blackwell, vol. 123(4), pages 1339-1384, October.
    2. Hilaire Gbodja Houeninvo, 2022. "Effects of health expenditures on infant and child mortality rates: A dynamic panel data analysis of 37 African countries," African Development Review, African Development Bank, vol. 34(2), pages 255-267, June.
    3. Blázquez-Fernández, Carla & González-Prieto, Noelia & Moreno-Mencía, Patricia, 2013. "Pharmaceutical Expenditure as a Determinant of Health Outcomes in EU Countries/El gasto farmacéutico como determinante de los resultados en salud en países de la UE," Estudios de Economia Aplicada, Estudios de Economia Aplicada, vol. 31, pages 379-396, Septiembr.
    4. Gallet, Craig A. & Doucouliagos, Hristos, 2017. "The impact of healthcare spending on health outcomes: A meta-regression analysis," Social Science & Medicine, Elsevier, vol. 179(C), pages 9-17.
    5. Mihajlo Jakovljevic & Paula Odete Fernandes & João Paulo Teixeira & Nemanja Rancic & Yuriy Timofeyev & Vladimir Reshetnikov, 2019. "Underlying Differences in Health Spending Within the World Health Organisation Europe Region—Comparing EU15, EU Post-2004, CIS, EU Candidate, and CARINFONET Countries," IJERPH, MDPI, vol. 16(17), pages 1-15, August.

    More about this item

    Statistics

    Access and download statistics

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:vrs:manmen:v:16:y:2012:i:1:p:203-215:n:15. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    If CitEc recognized a bibliographic reference but did not link an item in RePEc to it, you can help with this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Peter Golla (email available below). General contact details of provider: https://www.sciendo.com .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.